Aggregator

Cochrane Neuromuscular seeks Assistant Managing Editor/Information Specialist role - London, UK

3 years 9 months ago

Assistant Managing Editor/Information Specialist, fixed term to 31 March 2023
Deadline to apply: 7 March 2022
London, UK

Cochrane Neuromuscular is seeking an Information Specialist/Assistant Managing Editor on a fixed-term basis to 31 March 2023. This is an opportunity to contribute to evidence synthesis for the benefit of people affected by neuromuscular diseases.

Cochrane Neuromuscular is part of Cochrane, an independent, global organisation dedicated to synthesising research evidence to improve health. The group publishes reviews of evidence in neuromuscular disease in The Cochrane Database of Systematic Reviews (CDSR). Cochrane Neuromuscular is hosted by University College London NHS Hospitals Trust.

As postholder, you will have two primary areas of responsibility: literature searching, and assisting the Managing Editor in the management of submitted reviews. You will develop search strategies, run searches, and ensure correct documentation. Editorial tasks will include providing information to authors, checking manuscripts, overseeing peer review, tracking progress, and liaising between authors, editors, and reviewers. The appointee will also provide the review group with administrative support and may have the opportunity to assist review authors with systematic review tasks.

For details see nhsjobs.com. Closing date 7 March 2022.

Monday, February 28, 2022 Category: Jobs
Lydia Parsonson

Jesu li lijekovi protiv zgrušavanja krvi korisni za osobe s kroničnom bolešću bubrega?

3 years 9 months ago
Jesu li lijekovi protiv zgrušavanja krvi korisni za osobe s kroničnom bolešću bubrega? Što je proučavano u ovom sustavnom pregledu? Osobe s kroničnom bolešću bubrega (CKD, prema engl. chronic kidney disease) imaju povećan rizik od srčanih bolesti koje mogu blokirati dotok krvi u srce ili mozak, što uzrokuje srčani ili moždani udar. Lijekovi koji sprječavaju stvaranje krvnih ugrušaka (antitrombocitni lijekovi) mogu spriječiti smrt koju uzrokuju ugrušci u arterijama u općoj odrasloj populaciji. Međutim, osobe koje imaju CKD mogu imati manje koristi od tih lijekova, jer su kod njih krvni...

Imunosupresivno liječenje za fokalnu segmentalnu glomerulosklerozu u odraslih

3 years 9 months ago
Imunosupresivno liječenje za fokalnu segmentalnu glomerulosklerozu u odraslih Što je proučavano u ovom sustavnom pregledu? Nefrotski sindrom je stanje u kojem bubrezi propuštaju proteine iz krvi u mokraću. Fokalna segmentalna glomeruloskleroza (FSGS) potvrđena na biopsiji bubrega neuobičajen je uzrok nefrotskog sindroma, ali napreduje do zatajenja bubrega u otprilike polovici svih slučajeva. Može se podijeliti u tri skupine - primarni FSGS (misli se da je posljedica čimbenika koji cirkulira u krvi koji oštećuje bubrege), genetski (zbog mutacija u jednom ili više gena) i sekundarni zbog...

Metilfenidat s produljenim otpuštanjem za poremećaj s nedostatkom pažnje i hiperaktivnošću (ADHD) u odraslih

3 years 9 months ago
Metilfenidat s produljenim otpuštanjem za poremećaj s nedostatkom pažnje i hiperaktivnošću (ADHD) u odraslih Cilj sustavnog pregleda Ovaj sustavni pregled istražio je pozitivne i negativne učinke metilfenidata i usporedio ih s placebom ili drugim lijekovima kod odraslih osoba kojima je dijagnosticiran poremećaj s nedostatkom pažnje i hiperaktivnošću (engl. attention deficit hyperactivity disorder, ADHD). Posebna pažnja bila je usmjerena na učinke na svakodnevno funkcioniranje, kao što je broj dana izostanaka s posla i učinke na simptome ADHD-a i kvalitetu života koje procjenjuju sami...

Planiranje otpusta iz bolnice

3 years 9 months ago
Planiranje otpusta iz bolnice Koji je cilj ovog Cochraneovog sustavnog pregleda? Cilj Cochraneovog sustavnog pregleda bio je otkriti može li planiranje otpusta koje je prilagođeno pojedincu poboljšati kvalitetu pružene zdravstvene skrbi, smanjenjem odgođenog otpusta iz bolnice, smanjivanjem stope vraćanja u bolnicu i poboljšanjem zdravstvenog stanja pacijenata. Zanimalo nas je i koliko košta takva intervencija. Prikupili smo i analizirali sva relevantna istraživanja kako bismo odgovorili na ovo pitanje. Ovo je peto obnavljanje originalne inačice pregleda. Ključne poruke Kada ljudi napuste...

Učinci prehrane sa smanjenim udjelom glutena ili bez glutena za primarnu prevenciju kardiovaskularnih bolesti

3 years 9 months ago
Učinci prehrane sa smanjenim udjelom glutena ili bez glutena za primarnu prevenciju kardiovaskularnih bolesti Dosadašnje spoznaje Kardiovaskularne bolesti poremećaji su srca i krvnih žila, uključujući akutne koronarne i cerebrovaskularne događaje (kao što su infarkt miokarda i moždani udar). Otprilike 50% invaliditeta uzrokovanih kardiovaskularnim bolestima povezano je s manjkavom prehranom. To se posebno odnosi na prehrambeni gluten (protein koji se nalazi u određenim žitaricama) koji je povezan s velikim brojem nepovoljnih zdravstvenih ishoda. Na primjer, različiti probavni simptomi (kao...

University of Sydney seek Postdoc Research Associate

3 years 9 months ago
  • Full time fixed term until February 2023 (possibility of extension)
  • Great opportunity for an early career researcher to join a supportive and well respected team, making an impact in health based research
  • Base Salary $98,645 + 17% superannuation
  • Applications Close: Sunday 27 February 2022

About the opportunity
The NHMRC Clinical Trials Centre has an exciting opportunity for a Postdoctoral Research Associate to contribute to a range of projects using NextGen evidence synthesis methodologies and conducting meta-research.

Projects will likely include; finding and implementing ideal strategies in childhood obesity prevention interventions with the TOPCHILD collaboration, assessing eating disorder risk in obesity treatment, and conducting meta-research to find and reduce reasons for research waste and increase collaboration and coordination in research.

This is a research-only position, based at the NHMRC Clinical Trials Centre. The successful applicant will be working in the NextGen Evidence Synthesis team within the Evidence Integration Team. There will be an opportunity to develop NextGen evidence synthesis specialist skills, and to attend academic conferences to present project work. The successful applicant will be expected to make an active contribution to papers and new grant submissions arising from this work.

Your key responsibilities will be to:

  • undertake systematic reviews
  • work on individual participant data meta-analyses with large data sets
  • work with a large number of international collaborators and other stakeholders.

About you

  • a strong research background including a PhD qualification and competitive publication track record in a relevant field (systematic reviews, obesity, neonatology, epidemiology, public health, quantitative research or biostatistics)
  • formal qualifications in research methods, such as Masters level qualifications in epidemiology, biostatistics or public health is highly desired
  • ability to work independently, conceive, initiate, organise and manage projects
  • excellent communication and interpersonal skills
  • the successful applicant will combine quantitative research skills with excellent communication and scientific writing skills
  • experience in systematic reviews and meta-analyses is highly desirable
  • experience in research implementation and communication with a broad range of stakeholders (e.g. policy makers, consumers) is desirable, but not essential.

To keep our community safe, please be aware of our COVID safety precautions which form our conditions of entry for all staff, students and visitors coming to campus.

Sponsorship/work rights for Australia
Please note: Visa sponsorship is not available for this position. For a continuing position, you must be an Australian or New Zealand citizen or an Australian Permanent Resident.

Australian Temporary Residents currently employed at the University of Sydney may be considered for a fixed term contract for the length of their visa, depending on the requirements of the hiring area and the position.

Pre-employment checks
Your employment is conditional upon the completion of all role required pre-employment or background checks in terms satisfactory to the University. Similarly, your ongoing employment is conditional upon the satisfactory maintenance of all relevant clearances and background check requirements. If you do not meet these conditions, the University may take any necessary step, including the termination of your employment.

EEO statement
At the University of Sydney, our shared values include diversity and inclusion and we strive to be a place where everyone can thrive. We are committed to creating a University community which reflects the wider community that we serve. We deliver on this commitment through our people and culture programs, as well as key strategies to increase participation and support the careers of Aboriginal and Torres Strait Islander People, women, people living with a disability, people from culturally and linguistically diverse backgrounds, and those who identify as LGBTIQ. We welcome applications from candidates from all backgrounds.

How to apply

  • Applications (including a cover letter, CV, and any additional supporting documentation) can be submitted here 
  • If you are a current employee of the University or a contingent worker with access to Workday, please login into your Workday account and navigate to the Career icon on your Dashboard.  Click on USYD Find Jobs and apply.
  • For a confidential discussion about the role, or if you require reasonable adjustment or support filling out this application, please contact Lena Germinarios, Recruitment Operations, by email to lena.germinarios@sydney.edu.au
  • The University reserves the right not to proceed with any appointment.
  • Click to view the Position Description for this role.
  • Applications Close Sunday 27 February 2022 11:59 PM
Tuesday, February 22, 2022 Category: Jobs
Lydia Parsonson

Poboljšava li tjedna primjena paklitaksela preživljenje u usporedbi s primjenom svaka tri tjedna u početnom liječenju raka jajnika?

3 years 9 months ago
Poboljšava li tjedna primjena paklitaksela preživljenje u usporedbi s primjenom svaka tri tjedna u početnom liječenju raka jajnika? Dosadašnje spoznaje Karcinom jajnika šesti je najčešći karcinom u svijetu. Liječenje se sastoji od kombinacije operacije i kemoterapije (najčešće uz paklitaksel i karboplatin), s ciljem smanjenja ili odgode povratka raka (preživljenje bez napretka bolesti (engl. progression free survival (PFS)) i poboljšanja izgleda za preživljenje karcinoma (poznato kao ukupno preživljenje (engl. overall survival, OS)). Nekoliko kliničkih istraživanja ispitivalo je utječe li...

Angioplastika sama ili uz postavljanje stentova za liječenje suženja potključne arterije

3 years 9 months ago
Angioplastika sama ili uz postavljanje stentova za liječenje suženja potključne arterije Ključne poruke U medicinskoj literaturi nije pronađeno nijedno randomizirano kontrolirano istraživanje u kojem se uspoređuje učinkovitost i sigurnost ugradnje stenta (male cijevi koja djeluje poput skele i tako fizički drži krvnu žilu otvorenom) s angioplastikom (kirurškim zahvatom kojim se otvara suženje ili začepljenje krvne žile) za liječenje suženja potključne arterije (suženja ili začepljenja krvne žile). Trenutno nema dovoljno dokaza da bi se tvrdilo je li stentiranje učinkovitije od same...

Klonazepam kao antiepileptički lijek za liječenje osoba s novodijagnosticiranom epilepsijom

3 years 9 months ago
Klonazepam kao antiepileptički lijek za liječenje osoba s novodijagnosticiranom epilepsijom Dosadašnje spoznaje Monoterapija (liječenje jednim lijekom) najbolja je opcija za liječenje osoba s novodijagnosticiranom epilepsijom. Klonazepam je vrsta lijeka koja može smanjiti broj epileptičkih napadaja; on se ubraja u skupinu lijekova koji se nazivaju benzodiazepini. Pretražene su elektroničke baze podataka s ciljem kombiniranja rezultata svih dobro provedenih istraživanja na tu temu kako bi se utvrdilo koliko je klonazepam učinkovit u smanjenju broja napadaja kod osoba s novodijagnosticiranom...

Cochrane seeks Cochrane Clinical Answers Editor

3 years 9 months ago

Specifications: Part time (0.5FTE) Permanent/Consultancy contract dependant on location
Salary: £48,500 per annum full time equivalent
Location: Remote, flexible
Application Closing Date:  Friday 4 March 2022

We are looking for a part-time editor to join the Cochrane Clinical Answers (CCA) team.

CCAs provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane Reviews. They are designed to be actionable and to inform point-of-care decision-making and are published in the Cochrane Library (cochranelibrary.com).

Working with the CCA team, the editor will:

  • develop and edit a derivative product that supports the relevance and applicability of Cochrane Reviews, and their presentation and delivery to healthcare professionals;
  • ensure content is developed to best practice, delivered to agreed publishing date, and is consistent with Cochrane’s vision and values;
  • support the CCA Senior Editor with the editorial work and processes of the CCA team (including the CCA Editor in Chief and Cochrane’s publisher), with the aim of improving quality and efficiency through systems and guidance.

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information.

For this role, an understanding of Cochrane’s work and health research more generally is an advantage, but not essential.

The majority of Cochrane Central Executive staff are based in London, UK, but we will consider candidates from any location.



How to apply

  • For further information on the role and how to apply, please click here.  
  • The deadline to receive your application is by Friday 4 March.  
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Interviews to be held on: tbc
Thursday, February 17, 2022 Category: Jobs
Lydia Parsonson

Pomažu li antistatički stolci s preraspodjelom pritiska u sprječavanju dekubitusa?

3 years 9 months ago
Pomažu li antistatički stolci s preraspodjelom pritiska u sprječavanju dekubitusa? Ključne poruke Unatoč pretraživanju literature, nije pronađeno nijedno istraživanje koje se bavi time pomažu li antistatički stolci s preraspodjelom pritiska u sprječavanju ili liječenju dekubitusa. Ovo je važno znanstveno područje i potrebna su visokokvalitetna istraživanja kako bi se utvrdilo koriste li takve stolice osobama s rizikom od razvoja dekubitusa. Što su dekubitusi? Dekubitusi su ozljede kože i potkožnog tkiva uzrokovane dugotrajnim pritiskom. Sjedenje može biti važan dio procesa oporavka, ali...

Utječu li PARP inhibitori na smanjenje smrtnosti žena oboljelih od raka jajnika i koje nuspojave uzrokuju?

3 years 9 months ago
Utječu li PARP inhibitori na smanjenje smrtnosti žena oboljelih od raka jajnika i koje nuspojave uzrokuju? Ključne poruke U usporedbi s neaktivnim „lažnim“ lijekom (placebom), inhibitori PARP (skraćeno PARPi) u obliku tableta koje se uzimaju svaki dan nakon kemoterapije (u terapiji održavanja) postižu sljedeće učinke: - utječu u manjoj mjeri ili uopće ne utječu na životni vijek osobe s epitelnim rakom jajnika u uznapredovalom stadiju (ovaj zaključak se može promijeniti kada novi podaci postanu dostupni); - vjerojatno usporavaju napredak bolesti kod žena s novodijagnosticiranim epitelnim...

Operacija zamjene kuka u odraslih

3 years 10 months ago
Operacija zamjene kuka u odraslih Ovaj sustavni pregled procijenio je dokaze iz randomiziranih kontroliranih ispitivanja i kvazi-randomiziranih ispitivanja o prednostima i štetnim učincima različitih oblicima zamjene kuka koji se koriste za liječenje prijeloma u odraslih pacijenata. Dosadašnje spoznaje Prijelom kuka je prijelom gornjeg dijela bedrene kosti. Ove vrste prijeloma česte su u starijih osoba čije kosti mogu biti krhke zbog stanja zvanog osteoporoza. Jedna od metoda liječenja je zamjena slomljenog kuka umjetnim. To se može učiniti pomoću hemiartroplastike (HA), koja zamjenjuje dio...

Pečati za prevenciju karijesa mliječnih zubi

3 years 10 months ago
Pečati za prevenciju karijesa mliječnih zubi Istraživačko pitanje Može li pečaćenje griznih ploha mliječnih zuba u stražnjem dijelu ustiju spriječiti nastanak karijesa? Dosadašnje spoznaje Karijes je jedna od najčešćih bolesti djetinjstva koja može utjecati na opću dobrobit djeteta. Najčešće zahvaćeni zubi su stražnji zubi čije grizne površine nisu ravne i imaju utore (rupice i fisure) koji mogu zadržati ostatke hrane i bakterije, što dovodi do stvaranja karijesa. Osim toga, otvor ovih utora je toliko malen da vlakna četkice za zube ne mogu ući u njih u potpunosti, što otežava čišćenje....

Cochrane EPOC seek Systematic Reviewer

3 years 10 months ago

Location: Oxford
Salary: £33,309 to £40,927
Hours: Part Time
Contract Type: Fixed-Term/Contract
Closes: 11th March 2022
Job Ref: 155759

Oxford Population Health (The Nuffield Department of Population Health) contains world-renowned population health research groups and provides an excellent environment for multi-disciplinary research and teaching. The Clinical Trial Service Unit is a major international research institute within Oxford Population Health, and is one of the world’s leading centres for research into chronic diseases, such as cancer and heart disease.

As a Systematic Reviewer you will work with the Cochrane Effective Practice and Organisation of Care (EPOC) group in a multidisciplinary research environment. You will provide systematic review expertise to authors of ongoing EPOC systematic reviews, and take a lead or collaborate with existing authors on completing and publishing high priority EPOC reviews.

To be considered you will have a PhD in a health related subject (or equivalent experience), an understanding of statistics and experience of conducting and publishing systematic reviews. You will also have strong quantitative skills the ability to communication clearly with others.

  • Apply for the role here
  • The post is part-time (between 60-80%FTE) and fixed term to 31st March 2023.
  • The closing date for completed applications is 12.00 noon on 11th March 2022.   
  • Contact Email :recruit@ndph.ox.ac.uk
Thursday, February 10, 2022 Category: Jobs
Lydia Parsonson

Cochrane Connects Event, 1 March – Register Now

3 years 10 months ago

Register for Cochrane Connects meeting on research waste, including Cochrane-REWARD prize ceremony, and research integrity

Cochrane Connects - 1 March 17:00 – 18:00 GMT (check in your time zone)Register Now

Join us for the next Cochrane Connects meeting, which will focus on research waste and research integrity.

This special edition of Cochrane Connects will feature the Cochrane-REWARD prize ceremony. Since 2017, the prize has gathered, assessed and publicized local or pilot initiatives with the potential to reduce research waste if scaled up globally. We will be joined by representatives of the external prize committee, who will announce the winners of the first and second prizes live. The winners will share more about their initiatives in short presentations and answer audience questions.



There will also be an update on Cochrane’s research integrity activities from Senior Research Integrity Editor Prof Lisa Bero, followed by an opportunity for interactive discussion on what more Cochrane could do in this area, and on research waste in the future.

Cochrane Connects is a series of free online events open to everyone. You will have the opportunity to meet colleagues and peers, hear about and celebrate achievements from the community and take part in active discussions to help shape Cochrane for the future.

Register now by following the link here.

Monday, February 14, 2022
Lydia Parsonson

Millions of lives could be saved if health evidence and communication is put at forefront of pandemic preparedness

3 years 10 months ago

New Cochrane Convenes report recommends urgent action among those who fund, generate and use evidence to ensure the world is better prepared.

Two years in, it is clear that COVID-19 has created an unprecedented focus on health evidence for people working in governments, businesses and non-governmental organizations as well as members of the public. Responsible governments and other bodies have “followed the science” or claimed to.

Since the early days of the pandemic, Cochrane and other research synthesis organizations have been curating and analysing the thousands of studies being published on COVID-19 to help decision makers make sense of the evidence. The arrival of Omicron reinforced the need for timely evidence as decision makers across the globe scrambled to guide healthcare services and the public once again.

Dr Karla Soares-Weiser, Editor in Chief, Cochrane explains, “Like many others, I have been deeply concerned about the widening of existing inequities and the way that those already vulnerable have been disproportionately affected by the pandemic. As a community of evidence producers and users, we were not as prepared to respond to the COVID-19 pandemic as we could have been.”

Seeking to learn from the experience, in October 2021, Cochrane, invited key thought leaders from around the world to reflect on their experiences of producing, sharing and using evidence during the pandemic. Working with co-sponsor WHO, and co-organizer COVID-END, the event was convened with a view to making a call to action on areas for improvement. A resulting report, published today, discusses the challenges faced and presents recommendations from the meeting.

The report highlights three major challenges:

  • The evidence response to the COVID-19 pandemic has been inequitable –in terms of the focus of the evidence, who has been producing it and who it reaches
  • Current scientific methods, tools and processes have been pushed to their limits in trying to answer questions at the speed demanded
  • In the face of an infodemic, researchers have struggled to communicate scientific uncertainties and gain trust in the evidence 

Over the course of 2022, Cochrane will engage with a wider group of experts to take forward the most pressing recommendations, including:

  • Building support for creation of evidence synthesis unit/s in low and middle-income countries to help address global imbalance. This will mean some of the world’s poorest communities will have access to relevant evidence on what works in their region.
  • Investing in science communications which will strengthen our ability to communicate uncertainty in a way citizens understand, as well as being more proactive about science communication. 
  • Strengthening of tools, methods, processes and relationships to ensure a rapid and relevant evidence response at national and global levels for the next global health emergency. 

The report also calls on other key stakeholders in evidence generation and use to take urgent action:

  • Funders to provide resources to meet national and international research needs, which must address inequities; and particularly to fund evidence generation, communication, networks and infrastructure in low- and middle-income countries
  • Politicians to demand evidence; be transparent about how (and what) evidence is used in decision making; and to hold to account those deliberately creating and sharing mis/disinformation 
  • Researchers to support research transparency and data sharing; and raise the alarm about fraudulent studies
  • Science communicators to learn what works in communicating uncertainty, generating trust in evidence and countering mis/disinformation

Dr John Grove, Director of the Quality assurance, norms and standards department, Science division. WHO HQ, said,

“WHO, with our clear global mandate, will continue to bring focus to the priority questions, design what is most relevant for countries, combat misinformation, push for reducing inequities of access to the best science, and redouble activities to lead and coordinate these aspects of the response. Our main platform will continue to be building out a living approach to guidance development and implementation.”

 
Dr Karla Soares-Weiser, Editor in Chief, Cochrane said,

"We have all seen how the COVID-19 pandemic and its wider impacts have claimed many lives around the world. Cochrane Convenes was organized out of a sense of responsibility to learn from our experiences of the evidence response so that we can be better equipped for future health emergencies. 

The Cochrane community is a powerful and diverse global network, which we can harness to drive change. Of course, we cannot, and will not, do this in isolation. I hope that this report is therefore a call to action to funders, political leaders and other parts of the research community to join us in taking the recommendations forward."

Wednesday, February 16, 2022
Muriah Umoquit

Cochrane seeks Evidence Synthesis Methodology Editor

3 years 10 months ago

Specifications: Permanent
Salary: circa £40,000 per annum
Location: UK
Application Closing Date:  Friday 25 February 2022

Cochrane’s Methods Support Unit was established in 2019 to provide methodological support in the production of high quality, high priority Cochrane systematic reviews.

The Methods Support Unit provides guidance and hands on statistical and methods support to Cochrane systematic reviews, including those using complex methods or non-randomised study designs. The unit comprises two part time Statistical Editors and one full time Evidence Synthesis Methodology Editor.  

As Evidence Synthesis Methodology Editor, you will provide methodological support and general systematic review methods advice for reviews in process, field queries from the Community Support Team, and provide methods peer review as requested. You may also be required to provide subject matter expertise for the development of specific features in tools and software used in the production of Cochrane Reviews.

The role will require a very good understanding of methods such as the assessment of risk of bias for different study designs, application of GRADE and interpretation of findings in the review. An understanding of statistical meta-analysis methods is advantageous in the role, although specialist statistical editors in the unit will be able to provide this advice.

The majority of Cochrane Central Executive staff are located in London, UK, however flexible location or a part-time appointment are possible for the right candidate.

How to apply

  • For further information on the role and how to apply, please click here.  
  • The deadline to receive your application is by Friday 25 February.  
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
Wednesday, February 9, 2022 Category: Jobs
Lydia Parsonson

Trusted information needs to be protected on social media as much as misinformation needs to be challenged

3 years 10 months ago

Recent removal of Cochrane’s Instagram post and shadowban highlight the realities of Cochrane’s call against misinformation

Cochrane’s health evidence syntheses are recognised as the international gold standard for high quality, trusted information. Our reviews are used to support global and national health guidelines and policy. We advocate for evidence-informed healthcare and make our trusted evidence accessible and available to all. One way we do this is using social media to reach different audiences. 

In recent days, Cochrane has again been the subject of an Instagram misinformation blunder, with a post about a Cochrane Review on Ivermectin for prevention and treatment of COVID-19 being removed from the platform. Also Cochrane’s Instagram account has been denied the verification blue check mark several times. We are aware that other research publishers, such as the BMJ, have also experienced similar issues.

The first time this happened in November, Cochrane’s Instagram account was ‘shadowbanned’ for a few weeks; people could not tag or mention @cochraneorg on the platform. While little specifics were given, there was a notification that the account ‘repeatedly posted content that goes against Community Guidelines on false content about COVID-19 or vaccines.’ This shadowban happened just days after Cochrane helped lead a campaign to tackle misinformation for World Evidence-Based Healthcare Day and launched a course with Lifeology about identifying and preventing infodemics.

“The removal of our Cochrane post on Instagram comes just days before the launch of the Cochrane Convenes Report which calls for generating trust in evidence and countering mis/disinformation.” says Cochrane’s Editor in Chief, Dr Karla Soares-Weiser.

Drawing on experiences of the COVID-19 pandemic, Cochrane Convenes brought together leaders in health research and health evidence to explore and recommend the changes needed in evidence synthesis to prepare for and respond to future global health emergencies. The full report of the recommendations is being released 16 February.

“It’s not clear if there is an issue with Instagram’s algorithm or if the issue lies with people ‘gaming’ policies and reporting posts as misinformation when they are not. What is clear is that there is an issue with how you hold those deliberately creating and sharing mis/disinformation to account and how you form accreditation and approval for official sources of evidence that have met certain quality control standards. We need to make it easier for people to access trustworthy information – and that includes on social media.”

Cochrane is a proud supporter of WHO’s call to action on infodemic management and is currently collaborating with science communicators at Lifeology and the Association for Healthcare Social Media  and welcomes the opportunity to work directly with social media platforms and with others interested in tackling misinformation.

 

Tuesday, February 8, 2022
Muriah Umoquit